Gilead gets in on the microbiome game with a $38M pact, up to $1.5B in milestones
In what had been shaping up to be a major year for microbiome biotechs, Gilead is getting in on the action.
America’s newly most watched big biotech announced a four-year, $38 million upfront pact with Second Genome to identify biomarkers that can measure clinical response to Gilead’s inflammation and fibrosis drugs, among others, and to find up to 5 new inflammatory bowel disease targets or drug candidates. If all five of those candidates reach market — a rather unlikely occurrence — the deal could be worth up to $1.5 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.